Yazar "Bora, Huseyin" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Adjuvant radiotherapy for Stage I seminoma: A Single-institutional experience
    (Wolters Kluwer Medknow Publications, 2019) Kanyilmaz, Gul; Saricanbaz, Irem; Bora, Huseyin; Karahacioglu, Eray; Erkal, Eda Yirmibesoglu
    Objectives: There is no consensus regarding the management of Stage 1 seminomas following inguinal orchiectomy. In this study, we evaluated the treatment results and treatment-related toxicity for patients with Stage 1 seminomas treated with adjuvant radiotherapy (RT) at a single institution. Methods: Sixty-five patients who underwent adjuvant RT following orchiectomy for Stage 1 seminomas between January 1996 and December 2007 were retrospectively reviewed. The age, tumor location, histopathological type, stage, tumor size, RT field, and radiation dose were recorded for all patients. Results: The patients' ages ranged from 17 to 61 years (median, 37 years). Sixty-three patients (97%) were diagnosed with classical seminoma and the remaining two patients (3%) had spermatocytic seminoma. After orchiectomy, 37 patients (57%) received para-aortic RT and 28 patients (43%) received dog-leg field RT. RT was applied with 1.8u2 Gy/day fractionation and the median RT dose was 26 Gy (range, 20u38). Follow-up ranged from 0.3 to 18 years (median, 9.5 years). Local control had been achieved in all patients and all of them were alive with no evidence of disease. Fifty-one patients (77%) had at least 5 years of follow-up and 27 patients (41%) had at least 10 years of follow-up. Overall survival at 10 years was 100%. Conclusion: Although retrospective in nature, this single-institutional study provides useful information about the outcomes and toxicities associated with adjuvant RT in patients with Stage 1 seminomas reporting excellent disease control and survival rates at the expense of acceptable toxicity.
  • Küçük Resim Yok
    Öğe
    Prognostic Importance of Ki-67 Labeling Index in Grade II Glial Tumors
    (Kare Publ, 2018) Kanyilmaz, Gul; Onder, Hatice; Aktan, Meryem; Koc, Mehmet; Bora, Huseyin; Karahacioglu, Eray; Erkal, Haldun Sukru
    OBJECTIVE To date, several methods have been identified for predicting the prognostic subgroups of grade II gliomas; however, these methods have some limitations in predicting survival. So, we aimed to determine the predictive role of Ki-67 labeling, index (LI) on survival. METHODS Between 1995 and 2011, patients with grade II, gliomas were retrospectively analyzed. All patients received radiotherapy (RT). RESULTS This study included 78 patients with median 44 (range, 6-137) months follow-up. Patients aged >= 40 years had a poorer overall survival (OS) than those aged <10 years (p=0.04). Patients with gross total resection/ subtotal resection had a longer OS than those with biopsy/partial resection (p=0.001). If the disease had recurrence or progression during the follow-up period, the patients had a poorer OS (p=0.01). Patients with a Ki-67 LI >= 4% had a poorer OS than those with Ki-67 LI < 4%(p=0.001). The extent of resection, recurrence, or progression, and Ki-67 LI >= 4% were the independent prognostic factors for OS. CONCLUSION In our opinion, Ki-67 LI is an important prognostic factor for grade II gliomas, hut it cannot be used as a diagnostic measure alone. It must be used in combination with the other prognostic factors.
  • Küçük Resim Yok
    Öğe
    The Use of Complementary and Alternative Medicine Among Cancer Patients Treated with Radiotherapy
    (Kare Publ, 2022) Kanyilmaz, Gul; Akmansu, Muge; Bora, Huseyin; Yirmisbescoglu Erkal, Eda
    OBJECTIVE The purpose of this study was to determine: (1) the prevalence of complementary and alternative medicine (CAM) use (2) the characteristics of CAM users, (3) patients' source of information about CAM, (4) patients' perceived attitude of their physician regarding CAM use, and (5) the association between CAM use and Hospital Anxiety and Depression Scale (HADS). METHODS This descriptive-cross section study was conducted between June 2007 and December 2007. Three-hundred and six patients were asked to complete a questionnaire about the use of CAM along with HADS. RESULTS The prevalence of CAM use among cancer patients treated with radiotherapy was 35%. The patients with severe anxiety score were more likely to use CAM than the others. The younger age were found as predicting variables for CAM use. Majority of user patients wanted to add CAM to conventional therapies. CONCLUSION Oncologist might be aware of the CAM issue and talk to their patients about the use of CAM. The documentation of CAM use in the medical history might be advised at the time of initial consultation in radiotherapy centers. Although CAM use is a method that patients want to use in addition to conventional treatments, it is not clear that these methods can be used together safely. It is thought that there is a need for prospective and innovative studies in modern oncology centers.